Xellia expands in US with Fresenius Kabi buy
pharmafile | July 8, 2014 | News story | Manufacturing and Production | Fresenius Kabi, xellia
Anti-infective treatment provider Xellia has acquired Fresenius Kabi’s dedicated freeze-dried vial manufacturing facility in the US.
The deal also includes a continuous manufacturing and supply agreement with Fresenius Kabi USA. Financial details of the agreement have not been disclosed.
The manufacturing site is located close to the Research Triangle Park in North Carolina and is Xellia’s first US facility, which will significantly expand the company’s manufacturing capacity for injectable pharma products.
Xellia intends to retain all 80 staff currently employed at the site and will continue to manufacture certain products there for Fresenius Kabi. In the future, Xellia says in a statement it plans to employ more staff as it expands the facility further.
Carl-Åke Carlsson, chief executive of Xellia, says: “This is a great opportunity for us to expand our manufacturing capabilities into the US which is a key market for us. We have great respect for Fresenius Kabi and its employees, and have been in partnership with the company for years as a preferred, trusted supplier of active pharmaceutical ingredients.
“I believe this acquisition will be a win-win situation, benefiting both companies and our customers.”
John Ducker, president and chief executive of Fresenius Kabi USA, adds: “This agreement is part of our global strategy to optimise our manufacturing and supply network.
“Both companies are committed to assure a smooth and seamless transition for customers and employees. This transaction will have no impact on Fresenius Kabi’s ability to meet customer demand for the products we currently manufacture at the Raleigh site and we continue to work closely with the FDA to alleviate US drug shortages.”
This acquisition is part of the latest phase of Xellia’s on-going global expansion plans that include an investment of $2 million at the company’s Product and Innovation R&D Centre of Excellence in Zagreb, Croatia in May.
Ben Adams
Related Content
Polpharma Biologics and Fresenius Kabi partner to develop treatment for ulcerative colitis and Crohn’s disease
Polpharma Biologics has signed a global licensing agreement with Fresenius Kabi for the commercialisation of …
Prange Group and Adragos Pharma to acquire Fresenius Kabi’s manufacturing site
Prange Group and Adragos Pharma have announced the signing of definitive agreements with Fresenius Kabi …
Xellia Pharmaceuticals becomes member of Medicines for Europe
Xellia Pharmaceuticals, a manufacturer of specialty anti-infective treatments, has become a member of Medicines for …
